Purple Biotech (PPBT) Interest & Investment Income (2014 - 2026)
Purple Biotech's (PPBT) quarterly Interest & Investment Income came in at -$79000.0 in Q2 2026, down 8.22% year-over-year from -$86074.6 in Q2 2025, and down 295.0% quarter-over-quarter from -$20000.0 in Q1 2026.
Powered by 
Analysis
Purple Biotech (PPBT) Interest & Investment Income (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Interest & Investment Income for 13 consecutive years, with -$79000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Interest & Investment Income fell 8.22% year-over-year to -$79000.0 in Q2 2026; TTM through Jun 2026 was -$301000.0, a 57.78% increase from a year earlier, with the FY2025 full-year figure at -$424000.0, up 51.15% from the prior year.
- Interest & Investment Income was -$79000.0 for Q2 2026 at Purple Biotech, down from -$20000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at -$20000.0 in Q1 2026 and troughed at -$1.4 million in Q4 2023.
- A 5-year average of -$262000.0 and a median of -$122000.0 in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income sank 396.43% in 2023 and soared 82.68% in 2025, its largest moves.
- Over 5 years, Interest & Investment Income stood at -$576000.0 in 2022, then tumbled by 144.44% to -$1.4 million in 2023, then soared by 67.61% to -$456000.0 in 2024, then soared by 82.68% to -$79000.0 in 2025, then changed by 0.0% to -$79000.0 in 2026.
- The last three Interest & Investment Income figures came in at -$79000.0 (Q2 2026), -$20000.0 (Q1 2026), and -$79000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Purple Biotech | 286,924.75 | 228,924.75 | - | -79,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -79,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -79,000.00 |
| Sep 30, 2025 | -123,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -54,000.00 |
| Dec 31, 2024 | -456,000.00 |
| Sep 30, 2024 | -130,000.00 |
| Jun 30, 2024 | -121,000.00 |
| Mar 31, 2024 | -95,000.00 |
| Dec 31, 2023 | -1.41 Mn |
| Sep 30, 2023 | -708,000.00 |
| Jun 30, 2023 | -123,000.00 |
| Mar 31, 2023 | -278,000.00 |
| Dec 31, 2022 | -576,000.00 |
| Sep 30, 2022 | -248,000.00 |
| Jun 30, 2022 | -89,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -124,000.00 |
| Sep 30, 2021 | -68,000.00 |